HK1252845A1 - 劳拉替尼游离碱的结晶形式 - Google Patents
劳拉替尼游离碱的结晶形式 Download PDFInfo
- Publication number
- HK1252845A1 HK1252845A1 HK18112176.1A HK18112176A HK1252845A1 HK 1252845 A1 HK1252845 A1 HK 1252845A1 HK 18112176 A HK18112176 A HK 18112176A HK 1252845 A1 HK1252845 A1 HK 1252845A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ppm
- solid state
- nmr spectrum
- state nmr
- crystalline form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US62/199418 | 2015-07-31 | ||
| US201662352349P | 2016-06-20 | 2016-06-20 | |
| US62/352349 | 2016-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1252845A1 true HK1252845A1 (zh) | 2019-06-06 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112176.1A HK1252845A1 (zh) | 2015-07-31 | 2016-07-27 | 劳拉替尼游离碱的结晶形式 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (enExample) |
| EP (2) | EP3328867B9 (enExample) |
| JP (1) | JP6218253B2 (enExample) |
| KR (1) | KR102088188B1 (enExample) |
| CN (3) | CN107849060A (enExample) |
| AU (1) | AU2016304420B2 (enExample) |
| BR (1) | BR112017028604A2 (enExample) |
| CA (1) | CA2937257C (enExample) |
| CY (1) | CY1123689T1 (enExample) |
| DK (2) | DK3328867T3 (enExample) |
| ES (2) | ES2842302T3 (enExample) |
| FI (1) | FI3798222T3 (enExample) |
| HK (1) | HK1252845A1 (enExample) |
| HU (2) | HUE065536T2 (enExample) |
| MX (2) | MX395263B (enExample) |
| PL (2) | PL3328867T3 (enExample) |
| PT (2) | PT3798222T (enExample) |
| RU (1) | RU2018101363A (enExample) |
| SG (1) | SG10201913200XA (enExample) |
| SI (2) | SI3798222T1 (enExample) |
| TW (1) | TWI616449B (enExample) |
| WO (1) | WO2017021823A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2998885C (en) | 2015-09-24 | 2020-09-01 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2018232506A1 (en) * | 2017-06-22 | 2018-12-27 | Cyclenium Pharma Inc. | MACROCYCLIC COMPOUND LIBRARIES CONTAINING PYRIDINE AND METHODS FOR PREPARING AND USING SAME |
| SI3694863T1 (sl) * | 2017-10-10 | 2023-10-30 | Pfizer Inc. | Kristalna oblika hidrata proste baze lorlatiniba |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| WO2019209633A1 (en) | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| CN113260617A (zh) * | 2019-01-17 | 2021-08-13 | 辉瑞公司 | Cdk抑制剂的结晶形式 |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| CA2863892C (en) * | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| SI3694863T1 (sl) | 2017-10-10 | 2023-10-30 | Pfizer Inc. | Kristalna oblika hidrata proste baze lorlatiniba |
-
2016
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 HK HK18112176.1A patent/HK1252845A1/zh unknown
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en not_active Ceased
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 CN CN202310214099.4A patent/CN116063323B/zh active Active
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 MX MX2021002220A patent/MX395263B/es unknown
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active Active
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 MX MX2018001324A patent/MX382600B/es unknown
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11020376B2 (en) | Crystalline form of lorlatinib free base | |
| US11926636B2 (en) | Crystalline forms of lorlatinib maleate | |
| TWI775960B (zh) | 勞拉替尼(lorlatinib)游離鹼水合物之結晶型 | |
| RU2852836C1 (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| HK40093795A (en) | Crystalline form of lorlatinib free base | |
| HK40092368A (en) | Crystalline form of lorlatinib free base | |
| HK40029499B (en) | Crystalline form of lorlatinib free base hydrate |